Profiles the new grading system for prostate cancer introduced in 2015
Fully updated and revised new edition
Authored by recognized experts in their respective fields

This fully updated and revised new edition provides a comprehensive, state-of-the art review of this field, and will serve as a valuable resource for clinicians, surgeons and researchers with an interest in prostate cancer. The book reviews new data about molecular characteristics of the disease, profiles the new grading system for prostate cancer introduced in 2015, and provides new perspectives about imaging of prostate cancer, as well as the role of targeted biopsies. The text summarizes the role of biomarkers and MRI in patient selection and management and details the world wide results of active surveillance. Specific chapters address communication and ethical issues, QOL outcomes, economic aspects, and psycho-social aspects of surveillance. The role of focal therapy for low risk disease is summarized, and the data supporting preventive interventions during surveillance reviewed. This text will serve as a very useful resource for physicians and researchers dealing with, and interested in this common malignancy, as it provides a concise yet comprehensive summary of the current status of the field that will help guide patient management and stimulate investigative efforts.

Table of contents (21 chapters)
Cancer Overdiagnosis and Overtreatment
Klotz, Laurence
Pages 1-8
Can We Screen and Still Reduce Overdiagnosis?
Chiu, Peter Ka-Fung (et al.)
Pages 9-20
The Role of Fear in Overdiagnosis and Overtreatment
Heath, Iona
Pages 21-29
Ethical and Legal Considerations in Active Surveillance for Prostate Cancer
Venderbos, Lionne D. F.
Pages 31-39
Gleason 6 Tumors Should Still Be Labeled as Cancer
Marzo, Angelo M. (et al.)
Pages 41-52
Risk-Based Selection for Active Surveillance
Verbeek, Jan F. M. (et al.)
Pages 53-64
Surveillance at the Margins: Management of High-Volume Gleason 6, PSA 10, or Gleason 3 + 4
Klotz, Laurence
Pages 65-69
How Should Patients on Active Surveillance Be Followed?
Drost, Frank-Jan H. (et al.)
Pages 71-81
Triggers for Intervention
Mirtti, Tuomas (et al.)
Pages 83-94
MR Imaging in Prostate Tumor Volume Assessment: How Accurate?
Schoots, Ivo G. (et al.)
Pages 95-109
Can MRI Replace Biopsy in Men on Surveillance?
Giganti, Francesco (et al.)
Pages 111-119
Tissue-Based Markers for Risk Prediction
Reichard, Chad A. (et al.)
Pages 121-133
International AS Registry: The Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance Initiative
Bruinsma, Sophie M. (et al.)
Pages 135-147
Better-Informed Decision-Making to Optimize Patient Selection
Bellardita, Lara (et al.)
Pages 149-167
How Does QoL Compare Between Surveillance and Active Treatment?
Venderbos, Lionne D. F. (et al.)
Pages 169-181
The Potential Benefits of Diet and Physical Activity Among Active Surveillance Patients with Low-Burden Prostate Cancer
Kenfield, Stacey A. (et al.)
Pages 183-198
Is There a Role for Pharmacologic Manipulation to Prevent Progression in Men on Active Surveillance? The Role of 5-ARIs, Statins, and Metformin
Mano, Roy (et al.)
Pages 199-206
The Update of Active Surveillance Around the World: Utilization and Outcomes
Tosoian, Jeffrey J. (et al.)
Pages 207-216
Tissue Preservation: Active Surveillance and Focal Therapy as Complimentary Strategies
Rivas, Juan Gómez (et al.)
Pages 217-227
The Economics of Active Surveillance for Prostate Cancer
Lurvey, Robert B. (et al.)
Pages 229-237
Research Questions in Active Surveillance
Klotz, Laurence
Pages 239-241